Document is current
Any future updates will be listed below
-
Authors
Kolinger, Guilherme Domingues https://orcid.org/0000-0001-9505-4869
Sotolongo-Grau, Oscar https://orcid.org/0000-0002-9679-0670
Roé-Vellvé, Núria https://orcid.org/0000-0001-5583-8837
Tartari, Juan Pablo https://orcid.org/0000-0002-7548-2687
Sanabria, Ángela https://orcid.org/0000-0002-7501-9895
Pérez-Martínez, Esther
Koglin, Norman https://orcid.org/0000-0001-7583-8201
Stephens, Andrew W. https://orcid.org/0000-0001-5052-6586
Alegret, Montserrat https://orcid.org/0000-0002-8164-9500
Tárraga, Lluís https://orcid.org/0000-0002-8423-946X
Gurruchaga, Miren Jone
Ruiz, Agustín https://orcid.org/0000-0003-2633-2495
Boada, Mercè https://orcid.org/0000-0003-2617-3009
Bullich, Santiago https://orcid.org/0000-0001-5669-269X
Marquié, Marta https://orcid.org/0000-0002-0660-0950
,
Aguilera, N.
Alarcón-Martín, E.
Alegret, M.
Alllué, J. A.
Bayón-Bujan, P.
Bein, N.
Berthier, M.
Blázquez-Folch, J.
Boada, M.
Buendia, M.
Bullich, S.
Campos, F.
Calm-Salvans, B.
Cano, A.
Casales, F.
Cañabate, P.
Cañada, L.
Cuevas, C.
de Rojas, I.
Diego, S.
Domingues-Kolinger, G.
Escudero, J. M.
Espinosa, A.
Fernández, M. V.
Gailhajenet, A.
García-González, P.
Giménez, J.
Gómez-Chiari, M.
Guitart, M.
Gutiérrez-Rodríguez, P. C.
Hernández, I.
Ibarria, M.
Lafuente, A.
Lomeña, F.
Marquié, M.
Martín, E.
Moreno, M.
Morera, A.
Montrreal, L.
Muñoz, N.
Muñoz-Morales, A.
Niñerola, A.
Nogales, A. B.
Núñez, L.
Olivé, C.
Orellana, A.
Ortega, G.
Páez, A.
Pancho, A.
Pelejà, E.
Pérez-Martínez, E.
Pérez-Cordon, A.
Pérez-Grijalba, V.
Pascual-Lucas, M.
Perissinotti, A.
Preckler, S.
Puerta, R.
Pytel, V.
Ramis, M. I.
Rodríguez, J.
Roé-Vellvé, N.
Romero, J.
Rosende-Roca, M.
Ruiz, A.
Sanabria, A.
Sanz-Cartagena, P.
Sarasa, M.
Seguer, S.
Sotolongo-Grau, O.
Stephens, A.
Tartari, J. P.
Tárraga, L.
Tejero, M. A.
Terencio, J.
Torres, M.
Valero, S.
Vargas, L.
Vivas, A.
,
Barkhof, Frederik
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (115952, 115975, 115985)
Spanish ISCIII, Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (PI13/02434, PI16/01861, PI19/01240, PI19/01301, PI22/00258, PI22/01403)
European Union (PMP22/00022)
CIBERNED (CB06/05/2004, CB18/05/00010)
Joint program for neurodegenerative diseases (AC19/00097)
Agency for Innovation and Entrepreneurship (PR067/21)
ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (PI17/01474)
Programa Misiones de I+D en Inteligencia Artificial de la Secretaría de Estado de Digitalización e Inteligencia Artificial (SEDIA) del Ministerio de Asuntos Económicos y Transformación Digital (TARTAGLIA)
HORIZON EUROPE Marie Sklodowska-Curie Actions (796706)
Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (PI19/00335)
- License Information
-
More Information
Article History
Received: 20 December 2024
Accepted: 3 April 2025
First Online: 23 April 2025
Declarations
:
: A written consent was obtained from all participants prior to the enrolment in the study. The FACEHBI protocol received approval from the ethics committees of Hospital Clínic i Provincial in Barcelona, Spain (EudraCT number 2014–00079 - 38). The referral centre ethics committee approved the patient recruitment, and collection protocols were in accordance with ethical standards according to World Medical Association Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects.
: Not applicable.
: AR is member of the scientific advisory board of Landsteiner Genmed and Grifols SA. AR has stocks of Landsteiner Genmed.MB has consulted for Araclon, Avid, Grifols, Lilly, Nutricia, Roche, Eisai and Servier. She received fees from lectures and funds for research from Araclon, Biogen, Grifols, Nutricia, Roche and Servier. She reports grants/research funding from Abbvie, Araclon, Biogen Research Limited, Bioiberica, Grifols, Lilly, S.A, Merck Sharp & Dohme, Kyowa Hakko Kirin, Laboratorios Servier, Nutricia SRL, Oryzon Genomics, Piramal Imaging Limited, Roche Pharma SA, and Schwabe Farma Iberica SLU, all outside the submitted work. She has not received personal compensations from these organizations.MM has consulted for F. Hoffmann-La Roche Ltd and is a member of the Scientific Advisory Board of Biomarkers of Araclon.GDK, NRV, EPM, NK, AS and SB are employees of Life Molecular Imaging GmbH.The rest of authors declare that they have no competing interests.
